CD+4,CD+8及CD+4CD+8对于骨转移瘤治疗效果的监控作用

目的判断骨转移瘤患者经过放射性核素89SrCl2治疗后免疫学指标CD4 ,CD8 及CD4 /CD8 的变化及该指标对治疗效果的监控作用。方法选择经临床确诊的应用89SrCl2治疗的患者及正常对照组各24例。用流式细胞仪分别测定各患者治疗前、后及正常对照组CD4 ,CD8 及CD4 /CD8 值。每例患者均于治疗后第2,4和6个月行全身骨显像,记录骨转移病灶数及计算平均值。结果正常对照组CD4 ,CD4 /CD8 值高于骨转移瘤患者,而CD8 值低于骨转移瘤患者(P<0.05)。89SrCl2治疗后病灶数随CD4 增加、CD8 降低、CD4 /CD8 增加而相应减少。第4个月89SrCl2作用达峰值,各指标也达到极限值。结论CD4 ,CD8 ,CD4 /CD8 可以灵敏反映89SrCl2治疗效果,客观反映骨转移瘤病灶的变化。

CD4+,CD8+ and CD4+/CD8+ in estimating therapeutic effects of bone metastases

Objective: To judge the therapeutic effects of bone metastases by the percents of CD4 , CD8 , CD4 /CD8 before and after the treatment of 89SrCl2 in the patients with bone metastases. Methods: 24 patients who were diagnosed by clinic were treated with 89SrCl2. The CD4 , CD8 and CD4 /CD8 were detected by flow cytometry before and after 89SrCl2 treatment, as well in 24 controls. At the 2nd, 4th and 6th month after the administration, the bone scan with 99mTc-MDP was performed for all the patients and the quantities of bone metastases lesions were recorded. Result: The percents of CD4 and CD4 /CD8 in the controls group were higher than those in the patients with bone metastases, and the CD8 levels were lower (P<0.05). After the treatment of 89SrCl2, the CD4 and CD4 /CD8 levels increased and the CD8 level, the lesions decreased. These changes were the most obvious at the 4th month after the therapy. Conclusion: The CD4 , CD8 and CD4 /CD8 levels can sensitively reflect the therapeutic effects of 89SrCl2 and accurately estimate the conditions of bone metastases.